Which of the following patients would be an appropriate candidate for adjuvanted influenza vaccine (aIIV3)?

The adjuvanted influenza vaccine (aIIV3) is specifically designed to enhance the immune response, particularly in older adults who may have weaker immune systems. This formulation is particularly recommended for individuals aged 65 years and older, as they are at higher risk for severe flu-related complications.

In this scenario, the 67-year-old man with diabetes is an appropriate candidate for the adjuvanted influenza vaccine. He falls within the age group that receives particular benefit from this vaccine due to the natural decline of immune response with age. Furthermore, his underlying health condition—diabetes—also puts him at increased risk of complications from influenza, further supporting the use of the aIIV3 in this case.

In contrast, the other options represent individuals who either do not fall into the recommended categories for this specific vaccine or are younger and generally healthier, making standard influenza vaccines more suitable for them.